The role of the HSTS core is to eliminate or reduce to the greatest extent possible hazards associated with the use of hazardous biological, chemical, radioactive materials and hazardous wastes and to manage staff activities to reduce the risk of exposure and injury to individuals and the negative impact on the surrounding communities'natural environment. The Core members will interact with the GNL research community on a daily basis as an integral part of the research team. Core M will not only be responsible for the registration, recordkeeping and administration of the UTMB Select Agent program, but will also provide biosafety training, individual focused laboratory safety consultation and support. This core will provide education and hands-on training to promote techniques and procedures used within the research community. It will support the biological safety challenges that are present in today's cutting edge scientific endeavor. Consistency in biological safety practices within the research community is critical to the safety, security and reproducibility of the scientific outcome. The program will ensure that all GNL laboratorians have the same general biosafety skills and training at levels 2, 3, and 4 prior to entering a biocontainment laboratory on campus, thus ensuring that safety standards are observed and good practice is pursued. The core, which is managed by and Environmental Health and Safety Senior Consultant, will incorporate the campus'wellexperienced environmental health and safety staff and the University of Texas Medial Branch standing committees to facilitate and carry out the functions of HSTS Core M.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
National Biocontainment Laboratory Operation Cooperative Agreement (UC7)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas Medical Br Galveston
United States
Zip Code
Beasley, David W C; Brasel, Trevor L; Comer, Jason E (2016) First vaccine approval under the FDA Animal Rule. NPJ Vaccines 1:16013
Sha, Jian; Kirtley, Michelle L; Klages, Curtis et al. (2016) A Replication-Defective Human Type 5 Adenovirus-Based Trivalent Vaccine Confers Complete Protection against Plague in Mice and Nonhuman Primates. Clin Vaccine Immunol 23:586-600
Fitts, Eric C; Andersson, Jourdan A; Kirtley, Michelle L et al. (2016) New Insights into Autoinducer-2 Signaling as a Virulence Regulator in a Mouse Model of Pneumonic Plague. mSphere 1:
Tiner, Bethany L; Sha, Jian; Cong, Yingzi et al. (2016) Immunisation of two rodent species with new live-attenuated mutants of Yersinia pestis CO92 induces protective long-term humoral- and cell-mediated immunity against pneumonic plague. NPJ Vaccines 1:16020
Andersson, Jourdan A; Fitts, Eric C; Kirtley, Michelle L et al. (2016) New Role for FDA-Approved Drugs in Combating Antibiotic-Resistant Bacteria. Antimicrob Agents Chemother 60:3717-29
Tiner, Bethany L; Sha, Jian; Kirtley, Michelle L et al. (2015) Combinational deletion of three membrane protein-encoding genes highly attenuates yersinia pestis while retaining immunogenicity in a mouse model of pneumonic plague. Infect Immun 83:1318-38
Falzaran, D; Bente, D A (2015) Animal models for viral haemorrhagic fever. Clin Microbiol Infect :
Choi, Jin Huk; Schafer, Stephen C; Freiberg, Alexander N et al. (2015) Bolstering Components of the Immune Response Compromised by Prior Exposure to Adenovirus: Guided Formulation Development for a Nasal Ebola Vaccine. Mol Pharm 12:2697-711
Beasley, David W C; McAuley, Alexander J; Bente, Dennis A (2015) Yellow fever virus: genetic and phenotypic diversity and implications for detection, prevention and therapy. Antiviral Res 115:48-70
Tiner, Bethany L; Sha, Jian; Ponnusamy, Duraisamy et al. (2015) Intramuscular Immunization of Mice with a Live-Attenuated Triple Mutant of Yersinia pestis CO92 Induces Robust Humoral and Cell-Mediated Immunity To Completely Protect Animals against Pneumonic Plague. Clin Vaccine Immunol 22:1255-68

Showing the most recent 10 out of 42 publications